AstraZeneca’s Vandetanib Gets Extended U.S. FDA Review
This article is for subscribers only.
The U.S. Food and Drug Administration extended a review of AstraZeneca Plc’s vandetanib, an experimental treatment for advanced cases of a rare thyroid cancer, by three months.
The FDA required AstraZeneca to submit a risk evaluation and mitigation strategy as part of the review process, the London-based drugmaker said today in a statement. The plan has been submitted, and as a result, the agency has extended the review of the drug to April 7 from today, the company said.